The stamp still matters
Regulatory and evidence checkpoint · Reviewed November 3, 2026
What is known now—and what is still waiting for an answer?
Subject One approaches a counter carrying a folder marked “Submitted.” He asks for the “Approved” stamp. The clerk points to the empty space reserved for a decision. He takes his folder to the reading room instead. Waiting is part of the story, not a result.
What changes here
An application and positive trial findings do not equal approval. This journey records selected human studies, not a complete laboratory or animal dossier. [1] [2]
Read the study details & dates
Submission is a regulatory event
Novo announced its U.S. weight-management application for the fixed combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The pivotal human phase 3a trials were REDEFINE 1 (NCT05567796; component/placebo comparators) and REDEFINE 2 (NCT05394519; placebo). A filing is not an approval or a final label. [1]
Exploratory REDEFINE 1 analysis in women
A post hoc analysis in women from the same phase 3a trial reported estimated weight loss of 25.0% with CagriSema versus 3.0% with placebo under an efficacy estimand assuming adherence. Menopausal stages were assigned retrospectively; analyses were exploratory, without formal interaction tests or multiplicity-adjusted p-values. This does not establish a special treatment effect caused by menopause. [3]
Latest verified status in this review
Novo stated CagriSema was not approved in the United States or elsewhere. It announced presentations for November 14–17; forthcoming presentations are not results already reviewed here. No subsequent FDA approval was verified in this review. No recruitment claim is made. [2]
What this does not establish
Trial evidence concerns the studied product and populations; it does not validate improvised mixtures. Sponsor forecasts are not regulatory decisions. Long-term benefit–risk and any eventual label require their own evidence. All cited development studies were sponsored by Novo Nordisk.
Original sources
- Novo Nordisk sponsor release, December 18, 2025 — U.S. application submission
- Novo Nordisk sponsor release, October 29, 2026 — status and forthcoming congress presentations
- Novo Nordisk sponsor release, October 20, 2026 — exploratory REDEFINE 1 analyses in women
Sources reviewed November 3, 2026. Sponsor material is labeled; event dates are distinct from this editorial date. Trial identifiers identify the studies, not an invitation to enroll.
Journal update record
2026-11-03 · Opened this CagriSema journey with six sourced clinical/regulatory episodes. Preserved the different populations and analytical methods, reported serious harms and deaths without unsupported causality, and included the failed REDEFINE 4 non-inferiority endpoint. Latest verified sponsor status dated October 29, 2026; no subsequent FDA approval verified. This is an editorial addition, not a newly released trial result.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story